

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/10209 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 14/34**,  
C12N 9/10, C12P 13/08, C12N 1/21, 15/10, 15/63, C12Q  
1/68, A23L 1/305 // (C12P 13/08, C12R 1:15)

(21) International Application Number: **PCT/EP01/08220**

(22) International Filing Date: **17 July 2001 (17.07.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
100 38 050.6 2 August 2000 (02.08.2000) DE  
101 09 687.9 28 February 2001 (28.02.2001) DE

(71) Applicant: **DEGUSSA AG [DE/DE]**; Bennigsenplatz 1,  
40474 Düsseldorf (DE).


(72) Inventors: **BATHE, Brigitte**; Twieten 1, 33154 Salzkot-  
ten (DE). **MÖCKEL, Bettina**; Benrodestrasse 35, 40597  
Düsseldorf (DE). **PFEFFERLE, Walter**; Jahnstrasse 33,  
33790 Halle (Westf.) (DE). **HUTHMACHER, Klaus**;  
Lärchenweg 18, 63584 Gelnhausen (DE). **RÜCKERT,**  
**Christian**; Agnesstrasse 49, 33335 Gütersloh (DE).  
**KALINOWSKI, Jörn**; Lenbachstrasse 19, 33615 Biele-  
feld (DE). **PÜHLER, Alfred**; Am Waldschlösschen 2,  
33739 Bielefeld (DE). **BINDER, Michael**; Kalberkamp  
28, 33803 Steinhagen (Westf.) (DE). **GREISSINGER,**  
**Dieter**; Augasse 1f, 61194 Niddatal (DE). **THIERBACH,**  
**Georg**; Gunststrasse 21, 33613 Bielefeld (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: **NUCLEOTIDE SEQUENCES WHICH CODE FOR THE METH GENE**

Plasmid pCREmeth



(57) Abstract: The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), and processes for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the methH gene is present in enhanced form, and the use of the polynucleotide sequences as hybridization probes.

WO 02/10209 A1



MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## Nucleotide sequences which code for the methH gene

### Field of the Invention

The invention provides nucleotide sequences from coryneform bacteria which code for the methH gene and a process for the fermentative preparation of amino acids, in particular L-methionine, using bacteria in which the methH gene is enhanced.

### Prior Art

L-Amino acids, in particular L-methionine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

It is known that amino acids are prepared by fermentation from strains of coryneform bacteria, in particular *Corynebacterium glutamicum*. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the methionine analogue  $\alpha$ -methyl-methionine, ethionine, norleucine, N-acetylnorleucine, S-trifluoromethylhomocysteine, 2-amino-5-heprenoitic acid, seleno-methionine, methionine-sulfoximine, methoxine, 1-aminocyclopentane-carboxylic acid, or are auxotrophic for metabolites of regulatory

importance and produce amino acids, such as e.g. L-methionine, are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of  
5 Corynebacterium strains which produce L-amino acid, by amplifying individual amino acid biosynthesis genes and investigating the effect on the amino acid production.

#### Object of the Invention

The inventors had the object of providing new measures for  
10 improved fermentative preparation of amino acids, in particular L-methionine.

#### Summary of the Invention

When L-methionine or methionine are mentioned in the following, the salts, such as e.g. methionine hydrochloride  
15 or methionine sulfate are also meant by this.

The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the methH gene, chosen from the group consisting of

- 20 a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
- 25 b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
- c) polynucleotide which is complementary to the polynucleotides of a) or b), and

d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),

the polypeptide preferably having the activity of  
5 homocysteine methyltransferase II.

The invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:

- (i) the nucleotide sequence shown in SEQ ID No. 1, or
- 10 (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
- (iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii),  
15 and optionally.
- (iv) sense mutations of neutral function in (i).

The invention also provides

a polynucleotide comprising the nucleotide sequence as shown in SEQ ID No. 1;

20 a polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2,

a vector containing the polynucleotide according to the invention, in particular a shuttle vector or plasmid  
25 vector, and

and coryneform bacteria serving as the host cell, which contain the vector or in which the methH gene is enhanced.

The invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library, which comprises the complete  
5 gene with the polynucleotide sequence corresponding to SEQ ID No. 1, with a probe which comprises the sequence of the polynucleotide mentioned, according to SEQ ID No. 1 or a fragment thereof, and isolation of the DNA sequence mentioned.

#### 10 Detailed Description of the Invention

Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for  
15 homocysteine methyltransferase II or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence with that of the homocysteine methyltransferase II gene.

Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for homocysteine methyltransferase II can be prepared by the polymerase chain reaction (PCR).  
20

Such oligonucleotides which serve as probes or primers  
25 comprise at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides  
30 are optionally also suitable.

"Isolated" means separated out of its natural environment.

"Polynucleotide" in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.

5 "Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.

The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of homocysteine  
10 methyltransferase II, and also those which are at least 70%, preferably at least 80% and in particular which are at least 90% to 95% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.

15 The invention moreover provides a process for the fermentative preparation of amino acids, in particular L-methionine, using coryneform bacteria which in particular already produce amino acids, and in which the nucleotide sequences which code for the methH gene are enhanced, in particular over-expressed.

20 The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or  
25 using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is  
30 in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.

The microorganisms which the present invention provides can prepare L-amino acids, in particular L-methionine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be  
5 representatives of coryneform bacteria, in particular of the genus *Corynebacterium*. Of the genus *Corynebacterium*, there may be mentioned in particular the species *Corynebacterium glutamicum*, which is known among experts for its ability to produce L-amino acids.

10 Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum* (*C. glutamicum*), are in particular the known wild-type strains

*Corynebacterium glutamicum* ATCC13032  
*Corynebacterium acetoglutamicum* ATCC15806  
15 *Corynebacterium acetoacidophilum* ATCC13870  
*Corynebacterium thermoaminogenes* FERM BP-1539  
*Corynebacterium melassecola* ATCC17965  
*Brevibacterium flavum* ATCC14067  
*Brevibacterium lactofermentum* ATCC13869 and  
20 *Brevibacterium divaricatum* ATCC14020

or L-amino acid-producing mutants or strains prepared therefrom, such as, for example, the L-methionine-producing strain

*Corynebacterium glutamicum* ATCC21608.

25 The new *metH* gene from *C. glutamicum* which codes for the enzyme homocysteine methyltransferase II (EC 2.1.1.13) has been isolated.

To isolate the *metH* gene or also other genes of *C. glutamicum*, a gene library of this microorganism is first  
30 set up in *Escherichia coli* (*E. coli*). The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: *Gene und Klone, Eine Einführung in die Gentechnologie* (Verlag Chemie,



- Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example. A well-known gene library is that of the E. coli K-12 strain W3110 set up in  $\lambda$  vectors by Kohara et al. (Cell 50, 495-508 (1987)). Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was set up with the aid of the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in the E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575).
- Börmann et al. (Molecular Microbiology 6(3), 317-326 (1992)) in turn describe a gene library of C. glutamicum ATCC13032 using the cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980)). To prepare a gene library of C. glutamicum in E. coli it is also possible to use plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination-defective. An example of these is the strain DH5 $\alpha$ mc $r$ , which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649). The long DNA fragments cloned with the aid of cosmids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).
- The resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as e.g. that of Staden (Nucleic Acids Research 14, 217-232(1986)), that of Marck (Nucleic Acids Research 16, 1829-1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)).

The new DNA sequence of *C. glutamicum* which codes for the methH gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found. The amino acid sequence of the corresponding protein has furthermore been  
5 derived from the present DNA sequence by the methods described above. The resulting amino acid sequence of the methH gene product is shown in SEQ ID No. 2.

Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of  
10 the invention. In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are  
15 furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the  
20 function thereof. Information in this context can be found by the expert, inter alia, in Ben-Bassat et al. (Journal of Bacteriology 169:751-757 (1987)), in O'Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology  
25 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.

In the same way, DNA sequences which hybridize with SEQ ID  
30 No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention. Such oligonucleotides typically have a length of at least 15  
35 nucleotides.

Instructions for identifying DNA sequences by means of hybridization can be found by the expert, inter alia, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology (1991) 41: 255-260).

Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by the expert, inter alia, in the handbook by Gait: Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

It has been found that coryneform bacteria produce amino acids, in particular L-methionine, in an improved manner after over-expression of the methH gene.

To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-methionine production. The expression is likewise improved by measures to prolong the life of the mRNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over-expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.

Instructions in this context can be found by the expert, inter alia, in Martin et al. (Bio/Technology 5, 137-146 (1987)), in Guerrero et al. (Gene 138, 35-41 (1994)),

Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (1988)),  
in Eikmanns et al. (Gene 102, 93-98 (1991)), in European  
Patent Specification 0 472 869, in US Patent 4,601,893, in  
Schwarzer and Pühler (Bio/Technology 9, 84-87 (1991)), in  
5 Reinscheid et al. (Applied and Environmental Microbiology  
60, 126-132 (1994)), in LaBarre et al. (Journal of  
Bacteriology 175, 1001-1007 (1993)), in Patent Application  
WO 96/15246, in Malumbres et al. (Gene 134, 15 - 24  
(1993)), in Japanese Laid-Open Specification  
10 JP-A-10-229891, in Jensen and Hammer (Biotechnology and  
Bioengineering 58, 191-195 (1998)), in Makrides  
(Microbiological Reviews 60:512-538 (1996)) and in known  
textbooks of genetics and molecular biology.

By way of example, for enhancement the metH gene according  
15 to the invention was over-expressed with the aid of  
episomal plasmids. Suitable plasmids are those which are  
replicated in coryneform bacteria. Numerous known plasmid  
vectors, such as e.g. pZ1 (Menkel et al., Applied and  
Environmental Microbiology (1989) 64: 549-554), pEKEx1  
20 (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-1 (Sonnen  
et al., Gene 107:69-74 (1991)) are based on the cryptic  
plasmids pHM1519, pBL1 or pGA1. Other plasmid vectors, such  
as e.g. those based on pCG4 (US-A 4,489,160), or pNG2  
(Serwold-Davis et al., FEMS Microbiology Letters 66, 119-  
25 124 (1990)), or pAG1 (US-A 5,158,891), can be used in the  
same manner.

Plasmid vectors which are furthermore suitable are also  
those with the aid of which the process of gene  
amplification by integration into the chromosome can be  
30 used, as has been described, for example, by Reinscheid et  
al. (Applied and Environmental Microbiology 60, 126-132  
(1994)) for duplication or amplification of the hom-thrB  
operon. In this method, the complete gene is cloned in a  
plasmid vector which can replicate in a host (typically E.  
35 coli), but not in C. glutamicum. Possible vectors are, for

example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pGEM-T (Promega corporation, Madison, WI, USA), pCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 5 269:32678-84; US-A 5,487,993), pCR®Blunt (Invitrogen, Groningen, Holland; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)), pEM1 (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516) or pBGS8 (Spratt et al., 1986, Gene 41: 337-342). The plasmid vector which 10 contains the gene to be amplified is then transferred into the desired strain of *C. glutamicum* by conjugation or transformation. The method of conjugation is described, for example, by Schäfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for 15 transformation are described, for example, by Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of 20 a "cross over" event, the resulting strain contains at least two copies of the gene in question.

In addition, it may be advantageous for the production of amino acids, in particular L-methionine, to enhance one or more enzymes of the particular biosynthesis pathway, of 25 glycolysis, of anaplerosis, of the citric acid cycle or of amino acid export, in addition to the methH gene.

Thus for the preparation of amino acids, in particular L-methionine, one or more genes chosen from the group consisting of

- 30 • the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the tpi gene which codes for triose phosphate isomerase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),

- the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the pyc gene which codes for pyruvate carboxylase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- 5 • the lysC gene which codes for a feed-back resistant aspartate kinase (ACCESSION NUMBER P26512; EP-B-0387527; EP-A-0699759),
- the metA gene which codes for homoserine O-acetyltransferase (ACCESSION Number AF052652),
- 10 • the metB gene which codes for cystathionine gamma-synthase (ACCESSION Number AF126953),
- the aecD gene which codes for cystathionine gamma-lyase (ACCESSION Number M89931)
- the glyA gene which codes for serine
- 15 hydroxymethyltransferase (JP-A-08107788),
- the metY gene which codes for O-acetylhomoserine-sulfhydrylase (DSM 13556)

can be enhanced, in particular over-expressed.

It may furthermore be advantageous for the production of  
20 amino acids, in particular L-methionine, in addition to the enhancement of the methH gene, for one or more genes chosen from the group consisting of

- the thrB gene which codes for homoserine kinase (ACCESSION Number P08210),
- 25 • the ilvA gene which codes for threonine dehydratase (ACCESSION Number Q04513),
- the thrC gene which codes for threonine synthase (ACCESSION Number P23669),

- the ddh gene which codes for meso-diaminopimelate D-dehydrogenase (ACCESSION Number Y00151),
- the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1; DSM 13047),
- 5 • the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478; DSM 12969),
- the poxB gene which codes for pyruvate oxidase (DE: 1995 1975.7; DSM 13114)

10 to be attenuated, in particular for the expression thereof to be reduced.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a 15 corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein), and optionally combining these measures.

20 By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein.

25 In addition to over-expression of the methH gene it may furthermore be advantageous, for the production of amino acids, in particular L-methionine, to eliminate undesirable side reactions, (Nakayama: "Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

30 The microorganisms prepared according to the invention can be cultured continuously or discontinuously in the batch

- process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids, in particular L-methionine. A summary of known culture methods is
- 5 described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
- 10 The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General
- 15 Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).
- Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g.
- 20 palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
- Organic nitrogen-containing compounds, such as peptones,
- 25 yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can
- 30 be used individually or as a mixture.
- Organic and inorganic sulfur-containing compounds, such as, for example, sulfides, sulfites, sulfates and thiosulfates, can be used as a source of sulfur, in particular for the preparation of methionine.



Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of  
5 metals, such as e. g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances. Suitable precursors can moreover be added to the culture  
10 medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds,  
15 such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, such as e.g.  
20 antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to  
25 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.

The fermentation broths obtained in this way, in particular containing L-methionine, usually have a dry weight of 7.5  
30 to 25 wt.% and contain L-methionine. It is furthermore also advantageous if the fermentation is conducted in a sugar-limited procedure at least at the end, but in particular over at least 30% of the duration of the fermentation. That is to say, the concentration of utilizable sugar in the

fermentation medium is reduced to  $\geq 0$  to 3 g/l during this period.

The fermentation broth prepared in this manner, in particular containing L-methionine, is then further  
5 processed. Depending on requirements, all or some of the biomass can be removed from the fermentation broth by separation methods, such as e.g. centrifugation, filtration, decanting or a combination thereof, or it can be left completely in this. This broth is then thickened or  
10 concentrated by known methods, such as e.g. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration. This concentrated fermentation broth can then be worked up by methods of freeze drying, spray drying, spray granulation  
15 or by other processes to give a preferably free-flowing, finely divided powder.

This free-flowing, finely divided powder can then in turn be converted by suitable compacting or granulating processes into a coarse-grained, readily free-flowing,  
20 storable and largely dust-free product. In the granulation or compacting it is advantageous to employ conventional organic or inorganic auxiliary substances or carriers, such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders,  
25 gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.

"Free-flowing" is understood as meaning powders which flow unimpeded out of the vessel with the opening of 5 mm  
30 (millimeters) of a series of glass outflow vessels with outflow openings of various sizes (Klein, Seifen, Öle, Fette, Wachse 94, 12 (1968)).

As described here, "finely divided" means a powder with a predominant content ( $> 50\%$ ) with a particle size of 20 to

200  $\mu\text{m}$  diameter. "Coarse-grained" means products with a predominant content ( $> 50\%$ ) with a particle size of 200 to 2000  $\mu\text{m}$  diameter. In this context, "dust-free" means that the product contains only small contents ( $< 5\%$ ) with particle sizes of less than 20  $\mu\text{m}$  diameter. The particle size determination can be carried out with methods of laser diffraction spectrometry. The corresponding methods are described in the textbook on "Teilchengrößenmessung in der Laborpraxis" by R. H. Müller and R. Schuhmann, Wissenschaftliche Verlagsgesellschaft Stuttgart (1996) or in the textbook "Introduction to Particle Technology" by M. Rhodes, Verlag Wiley & Sons (1998).

"Storable" in the context of this invention means a product which can be stored for up to 120 days, preferably up to 52 weeks, particularly preferably 60 months, without a substantial loss ( $< 5\%$ ) of methionine occurring.

Alternatively, however, the product can be absorbed on to an organic or inorganic carrier substance which is known and conventional in feedstuffs processing, such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or mixed and stabilized with conventional thickeners or binders. Use examples and processes in this context are described in the literature (Die Mühle + Mischfüttertechnik 132 (1995) 49, page 817).

Finally, the product can be brought into a state in which it is stable to digestion by animal stomachs, in particular the stomach of ruminants, by coating processes ("coating") using film-forming agents, such as, for example, metal carbonates, silicas, silicates, alginates, stearates, starches, gums and cellulose ethers, as described in DE-C-4100920.

If the biomass is separated off during the process, further inorganic solids, for example added during the fermentation, are in general removed. In addition, the

animal feedstuffs additive according to the invention comprises at least the predominant proportion of the further substances, in particular organic substances, which are formed or added and are present in solution in the fermentation broth, where these have not been separated off by suitable processes.

In one aspect of the invention, the biomass can be separated off to the extent of up to 70%, preferably up to 80%, preferably up to 90%, preferably up to 95%, and particularly preferably up to 100%. In another aspect of the invention, up to 20% of the biomass, preferably up to 15%, preferably up to 10%, preferably up to 5%, particularly preferably no biomass is separated off.

These organic substances include organic by-products which are optionally produced, in addition to the L-methionine, and optionally discharged by the microorganisms employed in the fermentation. These include L-amino acids chosen from the group consisting of L-lysine, L-valine, L-threonine, L-alanine or L-tryptophan. They include vitamins chosen from the group consisting of vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B12 (cyanocobalamin), nicotinic acid/nicotinamide and vitamin E (tocopherol). They include furthermore organic acids which carry one to three carboxyl groups, such as, for example, acetic acid, lactic acid, citric acid, malic acid or fumaric acid. Finally, they also include sugars, such as, for example, trehalose. These compounds are optionally desired if they improve the nutritional value of the product.

These organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, can also be added, depending on requirements, as a concentrate or pure substance in solid or liquid form during a suitable process step. These organic substances mentioned can be added individually or as mixtures to the resulting or

concentrated fermentation broth, or also during the drying or granulation process. It is likewise possible to add an organic substance or a mixture of several organic substances to the fermentation broth and a further organic substance or a further mixture of several organic substances during a later process step, for example granulation.

The product described above is suitable as a feedstuffs additive, i.e. feed additive, for animal nutrition.

10 The L-methionine content of the animal feedstuffs additive is conventionally 1 wt.% to 80 wt.%, preferably 2 wt.% to 80 wt.%, particularly preferably 4 wt.% to 80 wt.%, and very particularly preferably 8 wt.% to 80 wt.%, based on the dry weight of the animal feedstuffs additive. Contents  
15 of 1 wt.% to 60 wt.%, 2 wt.% to 60 wt.%, 4 wt.% to 60 wt.%, 6 wt.% to 60 wt.%, 1 wt.% to 40 wt.%, 2 wt.% to 40 wt.% or 4 wt.% to 40 wt.% are likewise possible. The water content of the feedstuffs additive is conventionally up to 5 wt.%, preferably up to 4 wt.%, and particularly preferably less  
20 than 2 wt.%.

The invention accordingly also provides a process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths, which comprises the steps

- 25 a) culture and fermentation of an L-methionine-producing microorganism in a fermentation medium;
- b) removal of water from the L-methionine-containing fermentation broth (concentration);
- c) removal of an amount of 0 to 100 wt.% of the biomass  
30 formed during the fermentation; and

- d) drying of the fermentation broth obtained according to a) and/or b) to obtain the animal feedstuffs additive in the desired powder or granule form.

If desired, one or more of the following steps can  
5 furthermore be carried out in the process according to the invention:

- e) addition of one or more organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, to the products obtained,  
10 according to a), b) and/or c);
- f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to a) to d) for stabilization and to increase the storability; or
- 15 g) conversion of the substances obtained according to a) to e) into a form stable to the animal stomach, in particular rumen, by coating with film-forming agents.

The analysis of L-methionine can be carried out by ion exchange chromatography with subsequent ninhydrin  
20 derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190).

The process according to the invention is used for the fermentative preparation of amino acids, in particular L-methionine.

25 The following microorganism was deposited as a pure culture on 14th June 2001 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty:

- 30 • Escherichia coli DH5 $\alpha$ mc<sup>r</sup>/pCREmeth as DSM 14354.

The present invention is explained in more detail in the following with the aid of embodiment examples.

Example 1

- Preparation of a genomic cosmid gene library from  
5 *Corynebacterium glutamicum* ATCC 13032

Chromosomal DNA from *Corynebacterium glutamicum* ATCC 13032 was isolated as described by Tauch et al. (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product  
10 Description Sau3AI, Code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Code no. 1758250).

The DNA of the cosmid vector SuperCos1 (Wahl et al. (1987)  
15 Proceedings of the National Academy of Sciences USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, Product Description SuperCos1 Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme XbaI (Amersham Pharmacia, Freiburg, Germany, Product Description  
20 XbaI, Code no. 27-0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase. The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Code no. 27-0868-04). The cosmid DNA treated in this manner  
25 was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no. 27-0870-04). The ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene,  
30 La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217).

For infection of the *E. coli* strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) the cells were

taken up in 10 mM MgSO<sub>4</sub> and mixed with an aliquot of the phage suspension. The infection and titering of the cosmid library were carried out as described by Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/l ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.

### Example 2

#### 10 Isolation and sequencing of the methH gene

The cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme  
15 Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250). After  
20 separation by gel electrophoresis, the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

The DNA of the sequencing vector pZero-1, obtained from  
25 Invitrogen (Groningen, The Netherlands, Product Description Zero Background Cloning Kit, Product No. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04). The ligation of the cosmid  
30 fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then



electroporated (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) into the E. coli strain DH5 $\alpha$ mcr (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649) and plated out on LB agar (Lennox, 1955, 5 Virology, 1:190) with 50 mg/l zeocin.

The plasmid preparation of the recombinant clones was carried out with Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany). The sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, 10 Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was 15 used. The separation by gel electrophoresis and analysis of the sequencing reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, 20 Germany).

The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217-231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a continuous contig. 25 The computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).

The resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading 30 frame of 3662 base pairs, which was called the meth gene. The meth gene codes for a protein of 1221 amino acids.

### Example 3

Preparation of the strain *C. glutamicum* ATCC13032/pCREmeth

#### 3.1 Amplification of the methH gene

From the strain ATCC13032, chromosomal DNA was isolated by  
5 the method of Eikmanns et al. (Microbiology 140: 1817 -1828  
(1994)). Starting from the nucleotide sequences of the  
methionine biosynthesis genes methH (SEQ ID No. 1) of *C.*  
*glutamicum* ATCC13032, the following oligonucleotides were  
chosen for the polymerase chain reaction (PCR) (see SEQ ID  
10 No. 3. and SEQ ID No. 4):

methH-EVP5:

5'-GATCTAAGATCTAAAGGAGGACAACCATGTCTACTTCAGTTACTTCACCAGC-3'

methH-EVP3:

5'-GATCTAGTCGACCCCTCTCAAAGGTGTTAGAC-3'

15 The primers shown were synthesized by MWG-Biotech AG  
(Ebersberg, Germany) and the PCR reaction was carried out  
by the standard PCR method of Innis et al. (PCR Protocols.  
A Guide to Methods and Applications, 1990, Academic Press)  
with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim,  
20 Germany). With the aid of the polymerase chain reaction,  
the primers allow amplification of a DNA fragment 3718 bp  
in size, which carries the methH gene.

Furthermore, the primer methH-EVP5 contains the sequence for  
the cleavage site of the restriction endonuclease BglII and  
25 the primer methH-EVP3 the cleavage site of the restriction  
endonuclease SalI, which are marked by underlining in the  
nucleotide sequence shown above.

The methH fragment 3718 bp in size was cleaved with the  
restriction endonucleases BglII and SalI. The batch was  
30 separated by gel electrophoresis and the methH fragment  
(approx. 3700 bp) was then isolated from the agarose gel

with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

### 3.2 Cloning of meth in the vector pZ8-1

5 The *E. coli* - *C. glutamicum* shuttle expression vector pZ8-1 (EP 0 375 889) was used as the base vector for the expression.

10 DNA of the plasmid pZ8-1 was cleaved completely with the restriction enzymes BamHI and SalI and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250).

15 The meth fragment approx. 3700 bp in size isolated from the agarose gel in example 3.1 and cleaved with the restriction endonucleases BglII and SalI was mixed with the vector pZ8-1 prepared in this way and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no.27-0870-04).

20 The ligation batch was transformed in the *E. coli* strain DH5 $\alpha$ mc<sup>r</sup> (Hanahan, In: DNA cloning. A Practical Approach. Vol. I. IRL-Press, Oxford, Washington DC, USA). Selection of plasmid-carrying cells was made by plating out the transformation batch on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l kanamycin. After incubation overnight at 37°C, recombinant individual clones were selected.

25 Plasmid DNA was isolated from a transformant with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and checked by restriction cleavage. The resulting plasmid was called pCREmeth. The strain *E. coli* DH5 $\alpha$ mc<sup>r</sup>/pCREmeth was deposited as a pure culture on 14th June 2001 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms

30

and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty as DSM 14354.

### 3.3 Preparation of the strain *C. glutamicum* ATCC13032/pCREmeth

- 5 The vector pCREmeth obtained in example 3.2 was electroporated in the strain *C. glutamicum* ATCC13032 using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)). Selection of the plasmid-carrying cells took place on LBHIS agar comprising
- 10 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto-tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/l kanamycin. Incubation was carried out for 2 days at 33°C.

- Plasmid DNA was isolated from a transformant by
- 15 conventional methods (Peters-Wendisch et al., 1998, Microbiology 144, 915-927) and checked by restriction cleavage. The resulting strain was called ATCC13032pCREmeth.

#### Example 4

- 20 Preparation of methionine with the strain *C. glutamicum* ATCC13032/pCREmeth

- The *C. glutamicum* strain ATCC13032/pCREmeth obtained in example 3 was cultured in a nutrient medium suitable for the production of methionine and the methionine content in
- 25 the culture supernatant was determined.

- For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/l)) for 24 hours at 33°C. Starting from this agar plate culture, a preculture was seeded (10 ml
- 30 medium in a 100 ml conical flask). The medium MM was used as the medium for the preculture.

## Medium MM

CSL (corn steep liquor)	5 g/l
MOPS (morpholinopropanesulfonic acid)	20 g/l
Glucose (autoclaved separately)	50g/l
Salts:	
$(\text{NH}_4)_2\text{SO}_4$	25 g/l
$\text{KH}_2\text{PO}_4$	0.1 g/l
$\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$	1.0 g/l
$\text{CaCl}_2 \cdot 2 \text{H}_2\text{O}$	10 mg/l
$\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$	10 mg/l
$\text{MnSO}_4 \cdot \text{H}_2\text{O}$	5.0mg/l
Biotin (sterile-filtered)	0.01 mg/l
Vitamin B12 (sterile-filtered)	0.02 mg/l
Thiamine * $\text{HCl}$ (sterile-filtered)	0.2 mg/l
$\text{CaCO}_3$	25 g/l

The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions were then added, as well as the  $\text{CaCO}_3$ ,  
5 autoclaved in the dry state.

Kanamycin (25 mg/l) was added to this. The preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this preculture such that the initial OD (660 nm) of the main culture was  
10 0.1. Medium MM was also used for the main culture.

Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/l) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.

- 5 After 72 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of methionine formed was determined with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
- 10

The result of the experiment is shown in table 1.

Table 1

Strain	OD (660 nm)	Methionine mg/l
ATCC13032	12.3	1.4
ATCC13032/pCREmeth	14.3	5.3

Brief description of the figure:

- 15 • Figure 1: Plasmid pCREmeth

The abbreviations used in the figures have the following meaning:

- Km: Resistance gene for kanamycin
- meth: methH gene of *C. glutamicum*
- 20 Ptac: tac promoter
- T1 T2: Terminator T1T2 of the *rrnB* gene of *E. coli*
- rep: Plasmid-coded replication origin for *C. glutamicum* (of pHM1519)
- EcoRI: Cleavage site of the restriction enzyme EcoRI
- 25 SalI: Cleavage site of the restriction enzyme SalI

**What is claimed is:**

1. An isolated polynucleotide from coryneform bacteria,  
comprising a polynucleotide sequence chosen from the  
group consisting of
  - 5 a) polynucleotide which is identical to the extent of  
at least 70% to a polynucleotide which codes for a  
polypeptide which comprises the amino acid sequence  
of SEQ ID No. 2,
  - 10 b) polynucleotide which codes for a polypeptide which  
comprises an amino acid sequence which is identical  
to the extent of at least 70% to the amino acid  
sequence of SEQ ID No. 2,
  - c) polynucleotide which is complementary to the  
polynucleotides of a) or b), and
  - 15 d) polynucleotide comprising at least 15 successive  
nucleotides of the polynucleotide sequence of a),  
b) or c).
2. A polynucleotide as claimed in claim 1, wherein the  
polynucleotide is a preferably recombinant DNA which is  
20 capable of replication in coryneform bacteria.
3. A polynucleotide as claimed in claim 1, wherein the  
polynucleotide is an RNA.
4. A polynucleotide as claimed in claim 2, comprising the  
nucleic acid sequence as shown in SEQ ID No. 1.
- 25 5. A DNA as claimed in claim 2 which is capable of  
replication, comprising
  - (i) the nucleotide sequence shown in SEQ ID No. 1,  
or

- (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
  - (iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii), and optionally
  - (iv) sense mutations of neutral function in (i).
6. A polynucleotide sequence as claimed in claim 2, which codes for a polypeptide which comprises the amino acid sequence in SEQ ID No. 2.
  7. A coryneform bacterium in which the methH gene is enhanced, in particular over-expressed.
  8. A coryneform bacterium serving as the host cell, which contains a vector which carries a polynucleotide as claimed in claim 1.
  9. Escherichia coli strain DH5 $\alpha$ mcrr/pCREmethH as DSM 14354 deposited at the Deutsche Sammlung für Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures], Braunschweig, Deutschland.
  10. A process for the fermentative preparation of L-amino acids, in particular L-methionine, which comprises carrying out the following steps:
    - a) fermentation of the coryneform bacteria which produce the desired L-amino acid and in which at least the methH gene or nucleotide sequences which code for it are enhanced, in particular over-expressed;
    - b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and
    - c) isolation of the L-amino acid.



11. A process as claimed in claim 10, wherein bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 5 12. A process as claimed in claim 10, wherein bacteria in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
- 10 13. A process as claimed in claim 10, wherein a strain transformed with a plasmid vector is employed, and the plasmid vector carries the nucleotide sequence which codes for the methH gene.
- 15 14. A process as claimed in claim 10, wherein the expression of the polynucleotide(s) which code(s) for the methH gene is enhanced, in particular over-expressed.
15. A process as claimed in claim 10, wherein the catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide methH codes are increased.
- 20 16. A process as claimed in claim 10, wherein for the preparation of L-amino acids, in particular L-methionine, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of
- 25 16.1 the lysC gene which codes for a feed back resistant aspartate kinase,
- 16.2 the gap gene which codes for glycerolaldehyde 3-phosphate dehydrogenase,
- 16.3 the pgk gene which codes for 3-phosphoglycerate  
30 kinase,


- 16.4 the *pyc* gene which codes for pyruvate carboxylase,
- 16.5 the *tpi* gene which codes for triose phosphate isomerase
- 5 16.6 the *metA* gene which codes for homoserine O-acetyltransferase
- 16.7 the *metB* gene which codes for cystathionine gamma-synthase
- 10 16.8 the *aecD* gene which codes for cystathionine gamma-lyase
- 16.9 the *glyA* gene which codes for serine hydroxymethyltransferase
- 16.10 the *metY* gene which codes for O-acetylhomoserine-sulphydrylase
- 15 is or are enhanced or over-expressed, are fermented.
17. A process as claimed in claim 10, wherein for the preparation of L-amino acids, in particular L-methionine, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of
- 20 17.1 the *thrB* gene which codes for homoserine kinase
- 17.2 the *ilvA* gene which codes for threonine dehydratase
- 25 17.3 the *thrC* gene which codes for threonine synthase
- 17.4 the *ddh* gene which codes for meso-diaminopimelate D-dehydrogenase

- 17.5 the pck gene which codes for phosphoenol  
pyruvate carboxykinase
- 17.6 the pgi gene which codes for glucose 6-  
phosphate isomerase
- 5 17.7 the poxB gene which codes for pyruvate oxidase  
is or are attenuated are fermented.
18. A process as claimed in one or more of claims 10 to 17,  
wherein microorganisms of the species *Corynebacterium*  
*glutamicum* are employed.
- 10 19. A process as claimed in claim 18, wherein the  
*Corynebacterium glutamicum* strain ATCC13032/pCREmeth is  
employed.
20. A process for the preparation of an L-methionine-  
containing animal feedstuffs additive from fermentation  
15 broths, which comprises the steps
- a) culture and fermentation of an L-methionine-  
producing microorganism in a fermentation medium;
- b) removal of water from the L-methionine-containing  
fermentation broth (concentration);
- 20 c) removal of an amount of 0 to 100 wt.% of the  
biomass formed during the fermentation; and
- d) drying of the fermentation broth obtained according  
to b) and/or c) to obtain the animal feedstuffs  
additive in the desired powder or granule form.
- 25 21. A process as claimed in claim 20, wherein  
microorganisms in which further genes of the  
biosynthesis pathway of L-methionine are additionally  
enhanced are employed.

22. A process as claimed in claim 20, wherein microorganisms in which the metabolic pathways which reduce the formation of L-methionine are at least partly eliminated are employed.
- 5 23. A process as claimed in claim 20, wherein the expression of the polynucleotide(s) which code(s) for the methH gene is enhanced, in particular over-expressed.
- 10 24. A process as claimed in one or more of claims 20 to 23, wherein microorganisms of the species *Corynebacterium glutamicum* are employed.
25. A process as claimed in claim 24, wherein the *Corynebacterium glutamicum* strain ATCC13032/pCREmeth is employed.
- 15 26. A process as claimed in claim 20, wherein one or more of the following steps is or are additionally carried out:
- 20 e) addition of one or more organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, to the products obtained according to b), c) and/or d);
- 25 f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to b) to e) for stabilization and to increase the storability; or
- 30 g) conversion of the substances obtained according to b) to f) into a form stable to the animal stomach, in particular rumen, by coating with film-forming agents.

27. A process as claimed in claim 26, wherein a portion of the biomass is removed.
28. A process as claimed in claim 27, wherein up to 100% of the biomass is removed.
- 5 29. A process as claimed in claim 26, wherein the water content is up to 5 wt.%.
30. A process as claimed in claim 29, wherein the water content is less than 2 wt.%.
- 10 31. A process as claimed in claims 27, 28, 29, 30 or 31, wherein the film-forming agents are metal carbonates, silicas, silicates, alginates, stearates, starches, gums or cellulose ethers.
32. An animal feedstuffs additive prepared as claimed in claims 20 to 31.
- 15 33. An animal feedstuffs additive as claimed in claim 32, which comprises 1 wt.% to 80 wt.% L-methionine, D-methionine, D,L-methionine or a mixture thereof, based on the dry weight of the animal feedstuffs additive.
- 20 34. A process for discovering RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes which code for homocysteine methyltransferase II or have a high similarity with the sequence of the homocysteine methyltransferase II gene, which comprises employing the polynucleotide sequences as claimed in
- 25 claim 1, 2, 3 or 4 as hybridization probes.

Figure 1: Plasmid pCREmeth



## SEQUENCE PROTOCOL

&lt;110&gt; Degussa AG

5 &lt;120&gt; Nucleotide sequences which code for the methH gene

&lt;130&gt; 000365 BT

&lt;140&gt;

10 &lt;141&gt;

&lt;160&gt; 4

&lt;170&gt; PatentIn Ver. 2.1

15

&lt;210&gt; 1

&lt;211&gt; 4301

&lt;212&gt; DNA

20

&lt;213&gt; Corynebacterium glutamicum

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (385)..(4047)

&lt;223&gt; methH gene

25

&lt;400&gt; 1

taaggggtttt ggaggcattg gccgcgaacc catcgctggt catcccgggt ttgcgcatgc 60

30

cacgttcgta ttcataacca atcgcgatgc cttgagccca ccagccactg acatcaaagt 120

tgtccacgat gtgctttgcg atgtgggtgt gagtccaaga ggtggctttt acgtcgtcaa 180

gcaatttttag ccactcttcc cacggctttc cggtgccgtt gaggatagct tcaggggaca 240

35

tgctgtgtgt tgagccttgc ggagtggagt cagtcatgcy accgagacta gtggcgcttt 300

gcctgtgttg cttaggcggc gttgaaaatg aactacgaat gaaaagttcg ggaattgtct 360

40

aatccgtact aagctgtcta caca atg tct act tca gtt act tca cca gcc 411

Met Ser Thr Ser Val Thr Ser Pro Ala

1

5

45

cac aac aac gca cat tcc tcc gaa ttt ttg gat gcg ttg gca aac cat 459

His Asn Asn Ala His Ser Ser Glu Phe Leu Asp Ala Leu Ala Asn His

10 15 20 25

gtg ttg atc ggc gac ggc gcc atg ggc acc cag ctc caa ggc ttt gac 507

Val Leu Ile Gly Asp Gly Ala Met Gly Thr Gln Leu Gln Gly Phe Asp

30

35

40

50

ctg gac gtg gaa aag gat ttc ctt gat ctg gag ggg tgt aat gag att 555

Leu Asp Val Glu Lys Asp Phe Leu Asp Leu Glu Gly Cys Asn Glu Ile

45

50

55

55

ctc aac gac acc cgc cct gat gtg ttg agg cag att cac cgc gcc tac 603

Leu Asn Asp Thr Arg Pro Asp Val Leu Arg Gln Ile His Arg Ala Tyr

60

65

70

	ttt gag gcg gga gct gac ttg gtt gag acc aat act ttt ggt tgc aac	651
	Phe Glu Ala Gly Ala Asp Leu Val Glu Thr Asn Thr Phe Gly Cys Asn	
	75 80 85	
5	ctg cgg aac ttg gcg gat tat gac atc gct gat cgt tgc cgt gag ctt	699
	Leu Pro Asn Leu Ala Asp Tyr Asp Ile Ala Asp Arg Cys Arg Glu Leu	
	90 95 100 105	
10	gcc tac aag ggc act gca gtg gct agg gaa gtg gct gat gag atg ggg	747
	Ala Tyr Lys Gly Thr Ala Val Ala Arg Glu Val Ala Asp Glu Met Gly	
	110 115 120	
15	cgg ggc cga aac ggc atg cgg cgt ttc gtg gtt ggt tcc ctg gga cct	795
	Pro Gly Arg Asn Gly Met Arg Arg Phe Val Val Gly Ser Leu Gly Pro	
	125 130 135	
20	gga acg aag ctt cca tgg ctg ggc cat gca ccg tat gca gat ttg cgt	843
	Gly Thr Lys Leu Pro Ser Leu Gly His Ala Pro Tyr Ala Asp Leu Arg	
	140 145 150	
25	ggg cac tac aag gaa gca gcg ctt ggc atc atc gac ggt ggt ggc gat	891
	Gly His Tyr Lys Glu Ala Leu Gly Ile Ile Asp Gly Gly Gly Asp	
	155 160 165	
30	gcc ttt ttg att gag act gct cag gac ttg ctt cag gtc aag gct gcg	939
	Ala Phe Leu Ile Glu Thr Ala Gln Asp Leu Leu Gln Val Lys Ala Ala	
	170 175 180 185	
35	gtt cac ggc gtt caa gat gcc atg gct gaa ctt gat aca ttc ttg ccc	987
	Val His Gly Val Gln Asp Ala Met Ala Glu Leu Asp Thr Phe Leu Pro	
	190 195 200	
40	att att tgc cac gtc acc gta gag acc acc ggc acc atg ctc atg ggt	1035
	Ile Ile Cys His Val Thr Val Glu Thr Thr Gly Thr Met Leu Met Gly	
	205 210 215	
45	tct gag atc ggt gcc gcg ttg aca gcg ctg cag cca ctg ggt atc gac	1083
	Ser Glu Ile Gly Ala Ala Leu Thr Ala Leu Gln Pro Leu Gly Ile Asp	
	220 225 230	
50	atg att ggt ctg aac tgc gcc acc ggc cca gat gag atg agc gag cac	1131
	Met Ile Gly Leu Asn Cys Ala Thr Gly Pro Asp Glu Met Ser Glu His	
	235 240 245	
55	ctg cgt tac ctg tcc aag cac gcc gat att cct gtg tgg gtg atg cct	1179
	Leu Arg Tyr Leu Ser Lys His Ala Asp Ile Pro Val Ser Val Met Pro	
	250 255 260 265	
60	aac gca ggt ctt cct gtc ctg ggt aaa aac ggt gca gaa tac cca ctt	1227
	Asn Ala Gly Leu Pro Val Leu Gly Lys Asn Gly Ala Glu Tyr Pro Leu	
	270 275 280	
65	gag gct gag gat ttg gcg cag gcg ctg gct gga ttc gtc tcc gaa tat	1275
	Glu Ala Glu Asp Leu Ala Gln Ala Leu Ala Gly Phe Val Ser Glu Tyr	
	285 290 295	
70	ggc ctg tcc atg gtg ggt ggt tgt tgt ggc acc aca cct gag cac atc	1323
	Gly Leu Ser Met Val Gly Gly Cys Cys Gly Thr Thr Pro Glu His Ile	



	300	305	310	
5	cgt gcg gtc cgc gat gcg gtg gtt ggt gtt cca gag cag gaa acc tcc Arg Ala Val Arg Asp Ala Val Val Gly Val Pro Glu Gln Glu Thr Ser 315 320 325	1371		
10	aca ctg acc aag atc cct gca ggc cct gtt gag cag gcc tcc cgc gag Thr Leu Thr Lys Ile Pro Ala Gly Pro Val Glu Gln Ala Ser Arg Glu 330 335 340 345	1419		
15	gtg gag aaa gag gac tcc gtc gcg tcg ctg tac acc tcg gtg cca ttg Val Glu Lys Glu Asp Ser Val Ala Ser Leu Tyr Thr Ser Val Pro Leu 350 355 360	1467		
20	tcc cag gaa acc ggc att tcc atg atc ggt gag cgc acc aac tcc aac Ser Gln Glu Thr Gly Ile Ser Met Ile Gly Glu Arg Thr Asn Ser Asn 365 370 375	1515		
25	ggg tcc aag gca ttc cgt gag gca atg ctg tct ggc gat tgg gaa aag Gly Ser Lys Ala Phe Arg Glu Ala Met Leu Ser Gly Asp Trp Glu Lys 380 385 390	1563		
30	tgt gtg gat att gcc aag cag caa acc cgc gat ggt gca cac atg ctg Cys Val Asp Ile Ala Lys Gln Gln Thr Arg Asp Gly Ala His Met Leu 395 400 405	1611		
35	gat ctt tgt gtg gat tac gtg gga cga gac ggc acc gcc gat atg gcg Asp Leu Cys Val Asp Tyr Val Gly Arg Asp Gly Thr Ala Asp Met Ala 410 415 420 425	1659		
40	acc ttg gca gca ctt ctt gct acc agc tcc act ttg cca atc atg att Thr Leu Ala Ala Leu Leu Ala Thr Ser Ser Thr Leu Pro Ile Met Ile 430 435 440	1707		
45	gac tcc acc gag cca gag gtt att cgc aca ggc ctt gag cac ttg ggt Asp Ser Thr Glu Pro Glu Val Ile Arg Thr Gly Leu Glu His Leu Gly 445 450 455	1755		
50	gga cga agc atc gtt aac tcc gtc aac ttt gaa gac ggc gat ggc cct Gly Arg Ser Ile Val Asn Ser Val Asn Phe Glu Asp Gly Asp Gly Pro 460 465 470	1803		
55	gag tcc cgc tac cag cgc atc atg aaa ctg gta aag cag cac ggt gcg Glu Ser Arg Tyr Gln Arg Ile Met Lys Leu Val Lys Gln His Gly Ala 475 480 485	1851		
60	gcc gtg gtt gcg ctg acc att gat gag gaa ggc cag gca cgt acc gct Ala Val Val Ala Leu Thr Ile Asp Glu Glu Gly Gln Ala Arg Thr Ala 490 495 500 505	1899		
65	gag cac aag gtg cgc att gct aaa cga ctg att gac gat atc acc ggc Glu His Lys Val Arg Ile Ala Lys Arg Leu Ile Asp Asp Ile Thr Gly 510 515 520	1947		
70	agc tac ggc ctg gat atc aaa gac atc gtt gtg gac tgc ctg acc ttc Ser Tyr Gly Leu Asp Ile Lys Asp Ile Val Val Asp Cys Leu Thr Phe 525 530 535	1995		

	ccg atc tct act ggc cag gaa gaa acc agg cga gat ggc att gaa acc	2043
	Pro Ile Ser Thr Gly Gln Glu Glu Thr Arg Arg Asp Gly Ile Glu Thr	
	540 545 550	
5	atc gaa gcc atc cgc gag ctg aag aag ctc tac cca gaa atc cac acc	2091
	Ile Glu Ala Ile Arg Glu Leu Lys Lys Leu Tyr Pro Glu Ile His Thr	
	555 560 565	
10	acc ctg ggt ctg tcc aat att tcc ttc ggc ctg aac cct gct gca cgc	2139
	Thr Leu Gly Leu Ser Asn Ile Ser Phe Gly Leu Asn Pro Ala Ala Arg	
	570 575 580 585	
15	cag gtt ctt aac tct gtg ttc ctc aat gag tgc att gag gct ggt ctg	2187
	Gln Val Leu Asn Ser Val Phe Leu Asn Glu Cys Ile Glu Ala Gly Leu	
	590 595 600	
20	gac tct gcg att gcg cac agc tcc aag att ttg ccg atg aac cgc att	2235
	Asp Ser Ala Ile Ala His Ser Ser Lys Ile Leu Pro Met Asn Arg Ile	
	605 610 615	
25	gat gat cgc cag cgc gaa gtg gcg ttg gat atg gtc tat gat cgc cgc	2283
	Asp Asp Arg Gln Arg Glu Val Ala Leu Asp Met Val Tyr Asp Arg Arg	
	620 625 630	
30	acc gag gat tac gat ccg ctg cag gaa ttc atg cag ctg ttt gag ggc	2331
	Thr Glu Asp Tyr Asp Pro Leu Gln Glu Phe Met Gln Leu Phe Glu Gly	
	635 640 645	
35	gtt tct gct gcc gat gcc aag gat gct cgc gct gaa cag ctg gcc gct	2379
	Val Ser Ala Ala Asp Ala Lys Asp Ala Arg Ala Glu Gln Leu Ala Ala	
	650 655 660 665	
40	atg cct ttg ttt gag cgt ttg gca cag cgc atc atc gac ggc gat aag	2427
	Met Pro Leu Phe Glu Arg Leu Ala Gln Arg Ile Ile Asp Gly Asp Lys	
	670 675 680	
45	aat ggc ctt gag gat gat ctg gaa gca ggc atg aag gag aag tct cct	2475
	Asn Gly Leu Glu Asp Asp Leu Glu Ala Gly Met Lys Glu Lys Ser Pro	
	685 690 695	
50	att gcg atc atc aac gag gac ctt ctc aac ggc atg aag acc gtg ggt	2523
	Ile Ala Ile Ile Asn Glu Asp Leu Leu Asn Gly Met Lys Thr Val Gly	
	700 705 710	
55	gag ctg ttt ggt tcc gga cag atg cag ctg cca ttc gtg ctg caa tcg	2571
	Glu Leu Phe Gly Ser Gly Gln Met Gln Leu Pro Phe Val Leu Gln Ser	
	715 720 725	
60	gca gaa acc atg aaa act gcg gtg gcc tat ttg gaa ccg ttc atg gaa	2619
	Ala Glu Thr Met Lys Thr Ala Val Ala Tyr Leu Glu Pro Phe Met Glu	
	730 735 740 745	
65	gag gaa gca gaa gct acc gga tct gcg cag gca gag ggc aag ggc aaa	2667
	Glu Glu Ala Glu Thr Gly Ser Ala Gln Ala Glu Gly Lys Gly Lys	
	750 755 760	
70	atc gtc gtg gcc acc gtc aag ggt gac gtg cac gat atc ggc aag aac	2715
	Ile Val Val Ala Thr Val Lys Gly Asp Val His Asp Ile Gly Lys Asn	
	765 770 775	

	ttg	gtg	gac	atc	att	ttg	tcc	aac	aac	ggt	tac	gac	gtg	gtg	aac	ttg	2763
	Leu	Val	Asp	Ile	Ile	Leu	Ser	Asn	Asn	Gly	Tyr	Asp	Val	Val	Asn	Leu	
			780					785					790				
5																	
	ggc	atc	aag	cag	cca	ctg	tcc	gcc	atg	ttg	gaa	gca	gcg	gaa	gaa	cac	2811
	Gly	Ile	Lys	Gln	Pro	Leu	Ser	Ala	Met	Leu	Glu	Ala	Ala	Glu	Glu	His	
			795				800					805					
10																	
	aaa	gca	gac	gtc	atc	ggc	atg	tcg	gga	ctt	ctt	gtg	aag	tcc	acc	gtg	2859
	Lys	Ala	Asp	Val	Ile	Gly	Met	Ser	Gly	Leu	Leu	Val	Lys	Ser	Thr	Val	
	810					815					820					825	
15																	
	gtg	atg	aag	gaa	aac	ctt	gag	gag	atg	aac	aac	gcc	ggc	gca	tcc	aat	2907
	Val	Met	Lys	Glu	Asn	Leu	Glu	Glu	Met	Asn	Asn	Ala	Gly	Ala	Ser	Asn	
					830					835					840		
20																	
	tac	cca	gtc	att	ttg	ggc	gct	gag	ctg	acg	cgt	acc	tac	gtg	gaa		2955
	Tyr	Pro	Val	Ile	Leu	Gly	Gly	Ala	Ala	Leu	Thr	Arg	Thr	Tyr	Val	Glu	
				845					850					855			
25																	
	aac	gat	ctc	aac	gag	gtg	tac	acc	ggc	gag	gtg	tac	tac	gcc	cgt	gat	3003
	Asn	Asp	Leu	Asn	Glu	Val	Tyr	Thr	Gly	Glu	Val	Tyr	Tyr	Ala	Arg	Asp	
			860					865					870				
30																	
	gct	ttc	gag	ggc	ctg	cgc	ctg	atg	gat	gag	gtg	atg	gca	gaa	aag	cgt	3051
	Ala	Phe	Glu	Gly	Leu	Arg	Leu	Met	Asp	Glu	Val	Met	Ala	Glu	Lys	Arg	
		875					880					885					
35																	
	ggc	gaa	gga	ctt	gat	ccc	aac	tca	cca	gaa	gct	att	gag	cag	gag	aag	3099
	Gly	Glu	Gly	Leu	Asp	Pro	Asn	Ser	Pro	Glu	Ala	Ile	Glu	Gln	Ala	Lys	
	890					895					900					905	
40																	
	aag	aag	gag	gaa	cgt	aag	gct	cgt	aat	gag	cgt	tcc	cgc	aag	att	gcc	3147
	Lys	Lys	Ala	Glu	Arg	Lys	Ala	Arg	Asn	Glu	Arg	Ser	Arg	Lys	Ile	Ala	
					910					915					920		
45																	
	gag	gag	cgt	aaa	gct	aat	gag	gct	ccc	gtg	att	gtt	ccg	gag	cgt	tct	3195
	Ala	Glu	Arg	Lys	Ala	Asn	Ala	Ala	Pro	Val	Ile	Val	Pro	Glu	Arg	Ser	
				925					930					935			
50																	
	gat	gtc	tcc	acc	gat	act	cca	acc	gag	gca	cca	ccg	ttc	tggt	gga	acc	3243
	Asp	Val	Ser	Thr	Asp	Thr	Pro	Thr	Ala	Ala	Pro	Pro	Phe	Trp	Gly	Thr	
				940				945					950				
55																	
	cgc	att	gtc	aag	ggc	ctg	ccc	ttg	gag	gag	ttc	ttg	ggc	aac	ctt	gat	3291
	Arg	Ile	Val	Lys	Gly	Leu	Pro	Leu	Ala	Glu	Phe	Leu	Gly	Asn	Leu	Asp	
		955				960						965					
60																	
	gag	cgc	gcc	ttg	ttc	atg	ggg	cag	tggt	ggc	ctg	aaa	tcc	acc	cggt	ggc	3339
	Glu	Arg	Ala	Leu	Phe	Met	Gly	Gln	Trp	Gly	Leu	Lys	Ser	Thr	Arg	Gly	
	970					975					980					985	
65																	
	aac	gag	ggc	cca	agc	tat	gag	gat	ttg	gtg	gaa	act	gaa	ggc	cga	cca	3387
	Asn	Glu	Gly	Pro	Ser	Tyr	Glu	Asp	Leu	Val	Glu	Thr	Glu	Gly	Arg	Pro	
					990					995					1000		

cgc ctg cgc tac tgg ctg gat cgc ctg aag tct gag ggc att ttg gac 3435  
 Arg Leu Arg Tyr Trp Leu Asp Arg Leu Lys Ser Glu Gly Ile Leu Asp  
 1005 1010 1015

5 cac gtg gcc ttg gtg tat ggc tac ttc cca gcg gtc gcg gaa ggc gat 3483  
 His Val Ala Leu Val Tyr Gly Tyr Phe Pro Ala Val Ala Glu Gly Asp  
 1020 1025 1030

10 gac gtg gtg atc ttg gaa tcc ccg gat cca cac gca gcc gaa cgc atg 3531  
 Asp Val Val Ile Leu Glu Ser Pro Asp Pro His Ala Ala Glu Arg Met  
 1035 1040 1045

15 cgc ttt agc ttc cca cgc cag cag cgc ggc agg ttc ttg tgc atc gcg 3579  
 Arg Phe Ser Phe Pro Arg Gln Gln Arg Gly Arg Phe Leu Cys Ile Ala  
 1050 1055 1060 1065

20 gat ttc att cgc cca cgc gag caa gct gtc aag gac ggc caa gtg gac 3627  
 Asp Phe Ile Arg Pro Arg Glu Gln Ala Val Lys Asp Gly Gln Val Asp  
 1070 1075 1080

gtc atg cca ttc cag ctg gtc acc atg ggt aat cct att gct gat ttc 3675  
 Val Met Pro Phe Gln Leu Val Thr Met Gly Asn Pro Ile Ala Asp Phe  
 1085 1090 1095

25 gcc aac gag ttg ttc gca gcc aat gaa tac cgc gag tac ttg gaa gtt 3723  
 Ala Asn Glu Leu Phe Ala Ala Asn Glu Tyr Arg Glu Tyr Leu Glu Val  
 1100 1105 1110

30 cac ggc atc ggc gtg cag ctc acc gaa gca ttg gcc gag tac tgg cac 3771  
 His Gly Ile Gly Val Gln Leu Thr Glu Ala Leu Ala Glu Tyr Trp His  
 1115 1120 1125

35 tcc cga gtg cgc agc gaa ctc aag ctg aac gac ggt gga tct gtc gct 3819  
 Ser Arg Val Arg Ser Glu Leu Lys Leu Asn Asp Gly Gly Ser Val Ala  
 1130 1135 1140 1145

40 gat ttt gat cca gaa gac aag acc aag ttc ttc gac ctg gat tac cgc 3867  
 Asp Phe Asp Pro Glu Asp Lys Thr Lys Phe Phe Asp Leu Asp Tyr Arg  
 1150 1155 1160

ggc gcc cgc ttc tcc ttt ggt tac ggt tct tgc cct gat ctg gaa gac 3915  
 Gly Ala Arg Phe Ser Phe Gly Tyr Gly Ser Cys Pro Asp Leu Glu Asp  
 1165 1170 1175

45 cgc gca aag ctg gtg gaa ttg ctc gag cca ggc cgt atc ggc gtg gag 3963  
 Arg Ala Lys Leu Val Glu Leu Glu Pro Gly Arg Ile Gly Val Glu  
 1180 1185 1190

50 ttg tcc gag gaa ctc cag ctg cac cca gag cag tcc aca gac gcg ttt 4011  
 Leu Ser Glu Glu Leu Gln Leu His Pro Glu Gln Ser Thr Asp Ala Phe  
 1195 1200 1205

55 gtg ctc tac cac cca gag gca aag tac ttt aac gtc taacacottt 4057  
 Val Leu Tyr His Pro Glu Ala Lys Tyr Phe Asn Val  
 1210 1215 1220

gagagggaaa actttccgc acattgcaga tcgtgccact ttaactaagg ttgacggcat 4117

gattaaggcg attttctggg acatggacgg cacgatggtg gactctgagc cacagtgggg 4177

cattgctacc tacgagctca gcgaagccat gggccgcccgc ctcaccccgga agctccggga 4237  
 actcaccgtc ggctcgagcc tgccgcgcac catgcgctta tgccgagagc acgcaggcat 4297  
 5 taca 4301  
  
 <210> 2  
 10 <211> 1221  
 <212> PRT  
 <213> Corynebacterium glutamicum  
  
 <400> 2  
 15 Met Ser Thr Ser Val Thr Ser Pro Ala His Asn Asn Ala His Ser Ser  
     1                    5                    10                    15  
 Glu Phe Leu Asp Ala Leu Ala Asn His Val Leu Ile Gly Asp Gly Ala  
                     20                    25                    30  
 20 Met Gly Thr Gln Leu Gln Gly Phe Asp Leu Asp Val Glu Lys Asp Phe  
                     35                    40                    45  
 Leu Asp Leu Glu Gly Cys Asn Glu Ile Leu Asn Asp Thr Arg Pro Asp  
 25       50                    55                    60  
 Val Leu Arg Gln Ile His Arg Ala Tyr Phe Glu Ala Gly Ala Asp Leu  
     65                    70                    75                    80  
 30 Val Glu Thr Asn Thr Phe Gly Cys Asn Leu Pro Asn Leu Ala Asp Tyr  
                     85                    90                    95  
 Asp Ile Ala Asp Arg Cys Arg Glu Leu Ala Tyr Lys Gly Thr Ala Val  
                     100                    105                    110  
 35 Ala Arg Glu Val Ala Asp Glu Met Gly Pro Gly Arg Asn Gly Met Arg  
                     115                    120                    125  
 Arg Phe Val Val Gly Ser Leu Gly Pro Gly Thr Lys Leu Pro Ser Leu  
 40       130                    135                    140  
 Gly His Ala Pro Tyr Ala Asp Leu Arg Gly His Tyr Lys Glu Ala Ala  
     145                    150                    155                    160  
 45 Leu Gly Ile Ile Asp Gly Gly Gly Asp Ala Phe Leu Ile Glu Thr Ala  
                     165                    170                    175  
 Gln Asp Leu Leu Gln Val Lys Ala Ala Val His Gly Val Gln Asp Ala  
                     180                    185                    190  
 50 Met Ala Glu Leu Asp Thr Phe Leu Pro Ile Ile Cys His Val Thr Val  
                     195                    200                    205  
 Glu Thr Thr Gly Thr Met Leu Met Gly Ser Glu Ile Gly Ala Ala Leu  
 55       210                    215                    220  
 Thr Ala Leu Gln Pro Leu Gly Ile Asp Met Ile Gly Leu Asn Cys Ala  
     225                    230                    235                    240

Thr Gly Pro Asp Glu Met Ser Glu His Leu Arg Tyr Leu Ser Lys His  
 245 250 255  
 5 Ala Asp Ile Pro Val Ser Val Met Pro Asn Ala Gly Leu Pro Val Leu  
 260 265 270  
 Gly Lys Asn Gly Ala Glu Tyr Pro Leu Glu Ala Glu Asp Leu Ala Gln  
 275 280 285  
 10 Ala Leu Ala Gly Phe Val Ser Glu Tyr Gly Leu Ser Met Val Gly Gly  
 290 295 300  
 Cys Cys Gly Thr Thr Pro Glu His Ile Arg Ala Val Arg Asp Ala Val  
 305 310 315 320  
 15 Val Gly Val Pro Glu Gln Glu Thr Ser Thr Leu Thr Lys Ile Pro Ala  
 325 330 335  
 20 Gly Pro Val Glu Gln Ala Ser Arg Glu Val Glu Lys Glu Asp Ser Val  
 340 345 350  
 Ala Ser Leu Tyr Thr Ser Val Pro Leu Ser Gln Glu Thr Gly Ile Ser  
 355 360 365  
 25 Met Ile Gly Glu Arg Thr Asn Ser Asn Gly Ser Lys Ala Phe Arg Glu  
 370 375 380  
 Ala Met Leu Ser Gly Asp Trp Glu Lys Cys Val Asp Ile Ala Lys Gln  
 385 390 395 400  
 30 Gln Thr Arg Asp Gly Ala His Met Leu Asp Leu Cys Val Asp Tyr Val  
 405 410 415  
 35 Gly Arg Asp Gly Thr Ala Asp Met Ala Thr Leu Ala Ala Leu Leu Ala  
 420 425 430  
 Thr Ser Ser Thr Leu Pro Ile Met Ile Asp Ser Thr Glu Pro Glu Val  
 435 440 445  
 40 Ile Arg Thr Gly Leu Glu His Leu Gly Gly Arg Ser Ile Val Asn Ser  
 450 455 460  
 Val Asn Phe Glu Asp Gly Asp Gly Pro Glu Ser Arg Tyr Gln Arg Ile  
 465 470 475 480  
 45 Met Lys Leu Val Lys Gln His Gly Ala Ala Val Val Ala Leu Thr Ile  
 485 490 495  
 50 Asp Glu Glu Gly Gln Ala Arg Thr Ala Glu His Lys Val Arg Ile Ala  
 500 505 510  
 Lys Arg Leu Ile Asp Asp Ile Thr Gly Ser Tyr Gly Leu Asp Ile Lys  
 515 520 525  
 55 Asp Ile Val Val Asp Cys Leu Thr Phe Pro Ile Ser Thr Gly Gln Glu  
 530 535 540  
 Glu Thr Arg Arg Asp Gly Ile Glu Thr Ile Glu Ala Ile Arg Glu Leu  
 545 550 555 560

Lys Lys Leu Tyr Pro Glu Ile His Thr Thr Leu Gly Leu Ser Asn Ile  
 565 570 575  
 5 Ser Phe Gly Leu Asn Pro Ala Ala Arg Gln Val Leu Asn Ser Val Phe  
 580 585 590  
 Leu Asn Glu Cys Ile Glu Ala Gly Leu Asp Ser Ala Ile Ala His Ser  
 595 600 605  
 10 Ser Lys Ile Leu Pro Met Asn Arg Ile Asp Asp Arg Gln Arg Glu Val  
 610 615 620  
 Ala Leu Asp Met Val Tyr Asp Arg Arg Thr Glu Asp Tyr Asp Pro Leu  
 15 625 630 635 640  
 Gln Glu Phe Met Gln Leu Phe Glu Gly Val Ser Ala Ala Asp Ala Lys  
 645 650 655  
 20 Asp Ala Arg Ala Glu Gln Leu Ala Ala Met Pro Leu Phe Glu Arg Leu  
 660 665 670  
 Ala Gln Arg Ile Ile Asp Gly Asp Lys Asn Gly Leu Glu Asp Asp Leu  
 25 675 680 685  
 Glu Ala Gly Met Lys Glu Lys Ser Pro Ile Ala Ile Ile Asn Glu Asp  
 690 695 700  
 Leu Leu Asn Gly Met Lys Thr Val Gly Glu Leu Phe Gly Ser Gly Gln  
 30 705 710 715 720  
 Met Gln Leu Pro Phe Val Leu Gln Ser Ala Glu Thr Met Lys Thr Ala  
 725 730 735  
 35 Val Ala Tyr Leu Glu Pro Phe Met Glu Glu Glu Ala Glu Ala Thr Gly  
 740 745 750  
 Ser Ala Gln Ala Glu Gly Lys Gly Lys Ile Val Val Ala Thr Val Lys  
 755 760 765  
 40 Gly Asp Val His Asp Ile Gly Lys Asn Leu Val Asp Ile Ile Leu Ser  
 770 775 780  
 Asn Asn Gly Tyr Asp Val Val Asn Leu Gly Ile Lys Gln Pro Leu Ser  
 45 785 790 795 800  
 Ala Met Leu Glu Ala Ala Glu Glu His Lys Ala Asp Val Ile Gly Met  
 805 810 815  
 50 Ser Gly Leu Leu Val Lys Ser Thr Val Val Met Lys Glu Asn Leu Glu  
 820 825 830  
 Glu Met Asn Asn Ala Gly Ala Ser Asn Tyr Pro Val Ile Leu Gly Gly  
 835 840 845  
 55 Ala Ala Leu Thr Arg Thr Tyr Val Glu Asn Asp Leu Asn Glu Val Tyr  
 850 855 860

Thr Gly Glu Val Tyr Tyr Ala Arg Asp Ala Phe Glu Gly Leu Arg Leu  
 865 870 875 880  
 5 Met Asp Glu Val Met Ala Glu Lys Arg Gly Glu Gly Leu Asp Pro Asn  
 885 890 895  
 Ser Pro Glu Ala Ile Glu Gln Ala Lys Lys Lys Ala Glu Arg Lys Ala  
 900 905 910  
 10 Arg Asn Glu Arg Ser Arg Lys Ile Ala Ala Glu Arg Lys Ala Asn Ala  
 915 920 925  
 Ala Pro Val Ile Val Pro Glu Arg Ser Asp Val Ser Thr Asp Thr Pro  
 930 935 940  
 15 Thr Ala Ala Pro Pro Phe Trp Gly Thr Arg Ile Val Lys Gly Leu Pro  
 945 950 955 960  
 20 Leu Ala Glu Phe Leu Gly Asn Leu Asp Glu Arg Ala Leu Phe Met Gly  
 965 970 975  
 Gln Trp Gly Leu Lys Ser Thr Arg Gly Asn Glu Gly Pro Ser Tyr Glu  
 980 985 990  
 25 Asp Leu Val Glu Thr Glu Gly Arg Pro Arg Leu Arg Tyr Trp Leu Asp  
 995 1000 1005  
 Arg Leu Lys Ser Glu Gly Ile Leu Asp His Val Ala Leu Val Tyr Gly  
 1010 1015 1020  
 30 Tyr Phe Pro Ala Val Ala Glu Gly Asp Asp Val Val Ile Leu Glu Ser  
 1025 1030 1035 1040  
 35 Pro Asp Pro His Ala Ala Glu Arg Met Arg Phe Ser Phe Pro Arg Gln  
 1045 1050 1055  
 Gln Arg Gly Arg Phe Leu Cys Ile Ala Asp Phe Ile Arg Pro Arg Glu  
 1060 1065 1070  
 40 Gln Ala Val Lys Asp Gly Gln Val Asp Val Met Pro Phe Gln Leu Val  
 1075 1080 1085  
 Thr Met Gly Asn Pro Ile Ala Asp Phe Ala Asn Glu Leu Phe Ala Ala  
 1090 1095 1100  
 45 Asn Glu Tyr Arg Glu Tyr Leu Glu Val His Gly Ile Gly Val Gln Leu  
 1105 1110 1115 1120  
 50 Thr Glu Ala Leu Ala Glu Tyr Trp His Ser Arg Val Arg Ser Glu Leu  
 1125 1130 1135  
 Lys Leu Asn Asp Gly Gly Ser Val Ala Asp Phe Asp Pro Glu Asp Lys  
 1140 1145 1150  
 55 Thr Lys Phe Phe Asp Leu Asp Tyr Arg Gly Ala Arg Phe Ser Phe Gly  
 1155 1160 1165  
 Tyr Gly Ser Cys Pro Asp Leu Glu Asp Arg Ala Lys Leu Val Glu Leu  
 1170 1175 1180



Leu Glu Pro Gly Arg Ile Gly Val Glu Leu Ser Glu Glu Leu Gln Leu  
185 1190 1195 1200

5 His Pro Glu Gln Ser Thr Asp Ala Phe Val Leu Tyr His Pro Glu Ala  
1205 1210 1215

Lys Tyr Phe Asn Val  
1220

10

<210> 3  
<211> 52  
15 <212> DNA  
<213> Artificial sequence

<220>  
<223> Description of the artificial sequence: Primer  
20 meth-EVP5

<400> 3  
gatctaagat ctaaaggagg acaaccatgt ctacttcagt tacttcacca gc 52

25

<210> 4  
<211> 32  
<212> DNA  
<213> Artificial sequence

30

<220>  
<223> Description of the artificial sequence: Primer  
meth-EVP3

35 <400> 4  
gatctagtcg acccctctca aaggtgtag ac 32

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/EP 01/0220

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/34 C12N9/10 C12P13/08 C12N1/21 C12N15/10  
C12N15/63 C12Q1/68 A23L1/305 //(C12P13/08,C12R1:15)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, PAJ, BIOSIS, SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	COLE S T ET AL: "5-Methyltetrahydrofolate-homocysteine methyltransferase (EC 2.1.1.13) of Mycobacterium tuberculosis" , SWISS-PROT XP002175756	1-6, 34
Y	the whole document	7-33
X	DATABASE EMBL 'Online! Accession Number AB029371, 7 January 2000 (2000-01-07) XP002185491	1-6, 34
Y	the whole document	7-33
	---	
	--- -/---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

4 January 2002

Date of mailing of the international search report

22/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chavanne, F

# INTERNATIONAL SEARCH REPORT

Inter Application No

PCT/EP 01/08220

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 196 44 567 A (KERNFORSCHUNGSANLAGE JUELICH ;HOLLAND SWEETENER CO (NL)) 30 April 1998 (1998-04-30)	5
Y	abstract page 2, line 1 - line 3 page 3, line 9 page 3, line 18 - line 20 page 3, line 27 - line 30 page 3, line 36 - line 38 page 4, line 46 -page 5, line 6 page 6, line 45 - line 53 example 1 claims 1,5,14-19	7-33
X	WO 93 17112 A (GENENCOR INT) 2 September 1993 (1993-09-02)	5
Y	abstract page 1, line 1 -page 2, line 2; examples 1-7	7-33
X	EP 0 387 527 A (DEGUSSA) 19 September 1990 (1990-09-19)	5
Y	abstract page 2, line 9 - line 38 table 2	7-33
X	DATABASE WPI Section Ch, Week 199332 Derwent Publications Ltd., London, GB; Class B05, AN 1993-256072 XP002186615 & KR 9 208 381 B (CHEIL SUGAR CO), 26 September 1992 (1992-09-26)	5
Y	abstract	7-10, 13-15, 18-33
P,X	DATABASE WPI Section Ch, Week 200114 Derwent Publications Ltd., London, GB; Class B04, AN 2001-137957 XP002186616 & WO 01 00843 A (BASF AG), 4 January 2001 (2001-01-04) the whole document	1-40
P,X	EP 1 108 790 A (KYOWA HAKKO KOGYO KK) 20 June 2001 (2001-06-20) abstract table 1 SEQ ID No.1663	1-9,34

-/--

## INTERNATIONAL SEARCH REPORT

Intern: : Application No  
PCT/EP 01/0220

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KRAMER R: "Genetic and physiological approaches for the production of amino acids", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, VOL. 45, NR. 1, PAGE(S) 1-21 XP004036833 ISSN: 0168-1656 the whole document ---	
A	OLD I, SAINT GIRONS I, RICHAUD C: JOURNAL OF BACTERIOLOGY, vol. 175, no. 11, June 1993 (1993-06), pages 3689-3691, XP001037964 the whole document -----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08220

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19644567	A	30-04-1998	DE 19644567 A1	30-04-1998
			AU 4727897 A	22-05-1998
			WO 9818937 A1	07-05-1998
WO 9317112	A	02-09-1993	CA 2130347 A1	02-09-1993
			EP 0630406 A1	28-12-1994
			JP 7503855 T	27-04-1995
			WO 9317112 A1	02-09-1993
EP 0387527	A	19-09-1990	DE 3908201 A1	27-09-1990
			AT 107699 T	15-07-1994
			DE 59006167 D1	28-07-1994
			EP 0387527 A1	19-09-1990
			ES 2056263 T3	01-10-1994
			JP 3000087 B2	17-01-2000
			JP 3219885 A	27-09-1991
			SK 122890 A3	11-02-1999
KR 9208381	B	26-09-1992	KR 9208381 B1	26-09-1992
WO 0100843	A	04-01-2001	AU 5421300 A	31-01-2001
			WO 0100843 A2	04-01-2001
			AU 5559000 A	31-01-2001
			WO 0100844 A2	04-01-2001
			AU 5836900 A	31-01-2001
			WO 0100804 A2	04-01-2001
			AU 5421600 A	31-01-2001
			WO 0100805 A2	04-01-2001
			AU 5420500 A	31-01-2001
			WO 0100842 A2	04-01-2001
EP 1108790	A	20-06-2001	EP 1108790 A2	20-06-2001

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
WO 02/10209 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/34,  
C12N 9/10, C12P 13/08, C12N 1/21, 15/10, 15/63, C12Q  
1/68, A23L 1/305 // (C12P 13/08, C12R 1:15)

(21) International Application Number: PCT/EP01/08220

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
100 38 050.6 2 August 2000 (02.08.2000) DE  
101 09 687.9 28 February 2001 (28.02.2001) DE

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1,  
40474 Düsseldorf (DE).

(72) Inventors: BATHE, Brigitte; Twieten 1, 33154 Salzkot-  
ten (DE). MÖCKEL, Bettina; Benrodestrasse 35, 40597


Düsseldorf (DE). PFEFFERLE, Walter; Jahnstrasse 33,  
33790 Halle (Westf.) (DE). HUTHMACHER, Klaus;  
Lärchenweg 18, 63584 Gelnhausen (DE). RÜCKERT,  
Christian; Agnesstrasse 49, 33335 Gütersloh (DE).  
KALINOWSKI, Jörn; Lenbachstrasse 19, 33615 Biele-  
feld (DE). PÜHLER, Alfred; Am Waldschlösschen 2,  
33739 Bielefeld (DE). BINDER, Michael; Kalberkamp  
28, 33803 Steinhagen (Westf.) (DE). GREISSINGER,  
Dieter; Augasse 1f, 61194 Niddatal (DE). THIERBACH,  
Georg; Gunststrasse 21, 33613 Bielefeld (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: NUCLEOTIDE SEQUENCES WHICH CODE FOR THE METH GENE



(57) Abstract: The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70 % to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), and processes for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the metH gene coding for 5-methyltetrahydrofolate homocysteine methyltransferase (EC 2.1.1.13) is present in enhanced form, and the use of the polynucleotide sequences as hybridization probes.



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

4 April 2002

(15) Information about Correction:

see PCT Gazette No. 14/2002 of 4 April 2002, Section II

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**THIS PAGE BLANK (USPTO)**